Latham & Watkins Advises the Underwriters in Reneo Pharmaceuticals’ Initial Public Offering

A corporate deal team represents the underwriters in the offering.

April 09, 2021

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, has announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of US$15 per share, for total gross proceeds of approximately US$93.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Reneo.

Latham & Watkins LLP represents the underwriters in the offering with a corporate deal team led by Bay Area partner Brian Cuneo and San Diego partner Matt Bush, with Bay Area associates Richard Kim, Raul Gonzalez and Heather Durham. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang; on intellectual property matters by Bay Area/San Diego partner Chris Hazuka, with San Diego associates Robert Yeh and Michael Sweeney; on benefits and compensation matters by Bay Area partner Ashley Wagner; and on tax matters by Bay Area partner Grace Lee.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.